EP
KALV

Eversept Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Eversept Partners’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,925
Closed -$359K – 94
2020
Q4 		$359K Sell
18,925
-88,375
-82% -$1.52M 0.04% 56
2020
Q3 		$1.35M Buy
107,300
+17,494
+19% +$219K 0.3% 40
2020
Q2 		$1.09M Buy
+89,806
New +$955K 0.15% 60

Other funds holding KALV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Eversept Partners's KALV Position: Q1 2021 in Review

Eversept Partners sold out of KalVista Pharmaceuticals (KALV) in Q1 2021, closing a stake of 18,925 shares — an estimated $359K sold.

Eversept Partners first reported a position in KALV in Q2 2020 and held it in 3 quarters. The position peaked at $1.35M in Q3 2020. 117 funds tracked by Wall St. Rank hold KALV as of Q1 2021.

  • Eversept Partners reported no remaining KalVista Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Eversept Partners sold 18,925 KalVista Pharmaceuticals shares in Q1 2021, an estimated $359K.
  • Eversept Partners first reported a position in KalVista Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Eversept Partners's KalVista Pharmaceuticals position peaked at $1.35M in Q3 2020.
  • 117 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2021.

Based on Eversept Partners's 13F filing for Q1 2021, filed 13 May 2021.